We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Increased Clostridium Difficile Infections Due to Antibiotic Misuse

By LabMedica International staff writers
Posted on 11 Mar 2015
Changes in the epidemiology of Clostridium difficile infections have occurred since the emergence of the North American pulsed-field gel electrophoresis type 1 (NAP1) strain, which has been responsible for geographically dispersed hospital-associated outbreaks.

Clostridium difficile is a bacterium that causes colitis and inflammation of the colon and infection can occur through touching surfaces or items that are contaminated with feces, in which the bacteria are is shed. More...
People who are taking antibiotics for other illnesses are most prone to C. difficile infection as antibiotics can destroy some of the friendly bacteria in the gut, meaning it may be less protected against C. difficile.

A team of investigators led by those at the Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) identified all positive C. difficile test results from 88 inpatient and 33 outpatient laboratories serving residents in surveillance areas in 2011. A case of C. difficile infection was defined as a positive result on a C. difficile toxin or molecular assay of a stool specimen obtained from a surveillance-area resident at least one year of age who had not had a positive assay in the previous eight weeks. Recovered isolates underwent pulsed-field gel electrophoresis (PFGE) and also underwent polymerase-chain-reaction (PCR) assay to detect the presence of particular genes.

A total of 15,461 cases of C. difficile infection were identified in the 10 geographic areas; 65.8% were healthcare associated, but only 24.2% had onset during hospitalization. The North American pulsed-field gel electrophoresis type 1 (NAP1) strain was more prevalent among healthcare-associated infections than among community-associated infections. The study found that individuals aged 65 and older are particularly vulnerable to C. difficile infection. Around one in three cases occurred among patients in this age group, and they also accounted for two in three healthcare-associated C. difficile infections. What is more, around 80% of C. difficile-attributable deaths occurred in patients aged 65 or older.
The team also identified an increased risk of C. difficile infection among women and Caucasian individuals.

The CDC say these results indicate that improved antibiotic use and infection control needs to be put in place for outpatient health care, as well as inpatient facilities. Michael Bell, MD, deputy director of the Division of Healthcare Quality and Promotion at the CDC, said, “Overall, there are two main things that need to be improved. Number one is how antibiotics are being used, making sure that we use them when they're truly necessary and only for as long as necessary. The second element is to ensure rigorous infection control in all health care settings. C. difficile infections must be diagnosed quickly and correctly so that the infected patient can be cared for using the right infection control techniques.” The study was published on February 26, 2015, in the New England Journal of Medicine.

Related Links:

The Centers for Disease Control and Prevention 



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.